Furthermore, we found that high TGF-β3 mRNA levels predicted a decreased survival rate in women with grade II and III ovarian carcinoma, suggesting that TGF-β3 is worse at predicating prognosis in poorly differentiated and serous ovarian tumor patients. This evidence concerns the gene TGFB3 and ovarian carcinoma.